Assessment Of Safety Of UK-390,957

NCT ID: NCT00219609

Last Updated: 2012-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

1058 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether UK-390,957 is a safe treatment for premature ejaculation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ejaculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UK-390,957

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion Criteria

* No drug related serious adverse events
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Anaheim, California, United States

Site Status

Pfizer Investigational Site

Atherton, California, United States

Site Status

Pfizer Investigational Site

Beverly Hills, California, United States

Site Status

Pfizer Investigational Site

Laguna Woods, California, United States

Site Status

Pfizer Investigational Site

Newport Beach, California, United States

Site Status

Pfizer Investigational Site

Redwood City, California, United States

Site Status

Pfizer Investigational Site

San Diego, California, United States

Site Status

Pfizer Investigational Site

Tarzana, California, United States

Site Status

Pfizer Investigational Site

Walnut Creek, California, United States

Site Status

Pfizer Investigational Site

Aurora, Colorado, United States

Site Status

Pfizer Investigational Site

Waterbury, Connecticut, United States

Site Status

Pfizer Investigational Site

Aventura, Florida, United States

Site Status

Pfizer Investigational Site

New Port Richey, Florida, United States

Site Status

Pfizer Investigational Site

Evansville, Indiana, United States

Site Status

Pfizer Investigational Site

Fort Wayne, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Lexington, Kentucky, United States

Site Status

Pfizer Investigational Site

Madisonville, Kentucky, United States

Site Status

Pfizer Investigational Site

Metairie, Louisiana, United States

Site Status

Pfizer Investigational Site

Watertown, Massachusetts, United States

Site Status

Pfizer Investigational Site

Saint Clair Shores, Michigan, United States

Site Status

Pfizer Investigational Site

Minneapolis, Minnesota, United States

Site Status

Pfizer Investigational Site

Southhaven, Mississippi, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

Edison, New Jersey, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

Vorhees, New Jersey, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Endwell, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

West Seneca, New York, United States

Site Status

Pfizer Investigational Site

Williamsville, New York, United States

Site Status

Pfizer Investigational Site

Charlotte, North Carolina, United States

Site Status

Pfizer Investigational Site

Durham, North Carolina, United States

Site Status

Pfizer Investigational Site

Beachwood, Ohio, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Germantown, Tennessee, United States

Site Status

Pfizer Investigational Site

Knoxville, Tennessee, United States

Site Status

Pfizer Investigational Site

Memphis, Tennessee, United States

Site Status

Pfizer Investigational Site

Milan, Tennessee, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Pfizer Investigational Site

Milwuakee, Wisconsin, United States

Site Status

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Site Status

Pfizer Investigational Site

Spring Hill, Queensland, Australia

Site Status

Pfizer Investigational Site

Adelaide, South Australia, Australia

Site Status

Pfizer Investigational Site

Malvern, Victoria, Australia

Site Status

Pfizer Investigational Site

Nedlands, Western Australia, Australia

Site Status

Pfizer Investigational Site

Mistelbach, , Austria

Site Status

Pfizer Investigational Site

Salzburg, , Austria

Site Status

Pfizer Investigational Site

Barrie, Ontario, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Oakville, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Montréal, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Brno, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Lyon, , France

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Hanover, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

Beersheba, , Israel

Site Status

Pfizer Investigational Site

Haifa, , Israel

Site Status

Pfizer Investigational Site

Tel Aviv, , Israel

Site Status

Pfizer Investigational Site

Tel Litwinsky, , Israel

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Roma, , Italy

Site Status

Pfizer Investigational Site

Moelv, , Norway

Site Status

Pfizer Investigational Site

Oslo, , Norway

Site Status

Pfizer Investigational Site

Mysłowice, , Poland

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Skövde, , Sweden

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Balcali, Adana, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Samanpazarı, Ankara, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Balçova, İzmir, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Nr Lichfield, Staffordshire, United Kingdom

Site Status

Pfizer Investigational Site

Devon, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Canada Czechia France Germany Israel Italy Norway Poland Sweden Turkey (Türkiye) United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3871028

Identifier Type: -

Identifier Source: org_study_id